
1. hum vaccin. 2010 oct;6(10):784-91. epub 2010 oct 1.

trovax, recombinant modified vaccinia ankara virus encoding 5t4: lessons
learned future development.

kim dw(1), krishnamurthy v, bines sd, kaufman hl.

author information: 
(1)tumor immunology laboratory, department general surgery, rush university
medical center, chicago, il, usa.

there renewed interest developing vaccine immunotherapy the
treatment cancer. oncofetal antigen, 5t4, surface glycoprotein that
is expressed variety human adenocarcinomas rarely normal tissue.
5t4 plays important role tumor progression metastasis. expression
patterns functional role metastatic process suggest 5t4 good
target vaccine development. modified vaccinia virus ankara (mva) encoding
human 5t4 (designated trovax) demonstrated therapeutic effects murine tumor
models human cells recognized 5t4 epitopes hla-restricted manner. the
trovax vaccine subsequently evaluated clinical trials targeting
patients colorectal cancer, renal cell carcinoma hormone refractory
prostate cancer. herein, review results clinical studies, discuss
the lessons learned trials provide insight future
development trovax cancer vaccine.

doi: 10.4161/hv.6.10.13144 
pmid: 20975327  [indexed medline]

